Floatz logo

Pamiparib

Grade II Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Grade II Glioma cohort.

Asset / SponsorPhaseRating
Perampanel
Mayo Clinic
Phase 4B
FET
Thomas Hope
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 2CCC
Selpercatinib
National Cancer Institute (NCI)
Phase 2CCC
Ivosidenib
National Cancer Institute (NCI)
Phase 2CCC

View all 15 →

Same molecule, other indications

Pamiparib is also rated in:

ovarian carcinomaActive
B
Indicative · Phase 2
58 / 100
View asset →
ovarian cancerActive
B
Indicative · Phase 3
58 / 100
View asset →
grade III gliomaActive
B
Indicative · Phase 1/2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →